Inebilizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), HAS (France) and HIRA (South Korea) recommended or restricted inebilizumab, while CONITEC (Brazil), DMC (Denmark) and NYE METODER (Norway) did not recommend it.
The record spans 3.6 years, opening at HAS (France) on 19 Oct 2022 and running to 6 May 2026.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for inebilizumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 10 of 11 records date from 2023 or later.
Against its own class, inebilizumab is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class L04A average 78%.
HAS (France) was first to assess inebilizumab, on 19 Oct 2022; AWMSG (Wales) did not open a file until 6 May 2026 — a wide spread of 3.6 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed inebilizumab to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea).
HIRA (South Korea) is the only agency to have returned to inebilizumab, recording 2 separate entries.
10 of the 18 agencies in this archive hold a record for inebilizumab.
The full ledger for inebilizumab reads 3 not recommended, 2 recommended, 2 restricted and 2 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 6 May 2026 | Treatment for immunoglobulin G4-related disease | excluded, NICE appraised | source |
| CIPM (Spain) | 28 Apr 2026 | Indicaciones terapéuticas autorizadas: Trastorno del espectro de la neuromielitis óptica (TENMO) Uplizna está indicado e… | financed by the SNS · art. 92 a, c | source |
| HIRA (South Korea) | 2 Oct 2025 | 항아쿠아포린 -4(AQP4) 항체 양성인 성인 환자의 시신경척수염범주질환 | reimbursable only at the evaluated price | source |
| NYE METODER (Norway) | 21 Sep 2025 | Monoterapi for behandling av voksne pasienter med neuromyelitis opticaspektrumforstyrrelser (NMOSD) som er anti-akvapori… | not introduced | source |
| DMC (Denmark) | 27 Nov 2024 | Voksne med neuromyelitis optica spektrumforstyrrelse (NMOSD), som er anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropo… | Ikke anbefalet | source |
6 further decisions for inebilizumab, across 6 agencies, are not shown here. They include the most recent record on file, 6 May 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 11 decisions for inebilizumab from 10 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.